Greetings!

Welcome to the Monthly QPS Clinical Newsletter

Explore QPS expertise in studying ADCs in Oncology, learn more about the EU CTIS process in the QPS white paper, and read the latest scientific breakthroughs and insights on the QPS blog.

Using ADCs for Oncology Studies at QPS

Why choose QPS for Oncology Studies with ADCs?

QPS has vast expertise in antibody drug conjugate (ADC) research, including:

>700 Sites in our Global Site Network
Extensive Global KOL Network
Global Clinical Research Services
Specialized Expertise
Custom-Built Solutions
Experience with a Broad Range of Cancers

Download the White Paper

Antibody-Drug Conjugates (ADCs) in Oncology Drug Development

Understanding and Navigating Changes to Clinical Trial Management in the European Union

The European Union Clinical Trial Regulation 536/2014 (EU CTR) is transforming how clinical trials are managed across the EU and EEA. This regulation replaces the previous EU Clinical Trials Directive and introduces a unified approach to applications, assessments, and reporting, enhancing transparency and safety for participants.

Our white paper reviews the new system, its structure and functions, and provides recommendations for sponsors to keep their trials on track.

Download the White Paper

Understanding and Navigating Changes to Clinical Trial Management in the European Union

Discover the Future of Science on the QPS Blog

The Food Factor: How Diet Shapes Cancer Risk

New research continually adds to our knowledge of the effects of diet on cancer risk. Among recent findings, detailed below, are the protective effects of calcium-rich foods against colorectal cancer. Another study shows the importance of fiber and...

The Bigger Picture

A Measurable Slowdown

The Ultimate Guide to Oncology

Schedule a Meeting with QPS

Visit our website www.qps.com

or contact us at info@qps.com

for an appointment.

www.qps.com | info@qps.com

We use your email address exclusively for sending QPS newsletters with a special e-mail program. If you no longer wish to receive any mailings, simply use the "unsubscribe" link at the bottom. If you don't unsubscribe, we assume that this consent also applies to the system of the GDPR. (Data protection notice: According to Art. 7 GDPR, the consent can of course also be withdrawn at any time after May 25, 2018.)